| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of mepivacaine-d3 is the voltage-gated sodium channel on neuronal cell membranes. As a deuterated analog of mepivacaine, it binds to specific sites on these sodium channels, inhibiting sodium influx and membrane depolarization. This action temporarily blocks nerve signal conduction, resulting in local anesthesia. However, mepivacaine-d3 is primarily used as a research tool for analytical purposes rather than for its anesthetic effects, as the deuterium labeling allows for precise tracking and quantification in biological samples.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Mepivacaine-d3 does not have specific in vitro biological activity as it is used as an analytical standard rather than a therapeutic agent. However, as a deuterated analog of mepivacaine, it shares the same mechanism of action as the parent compound: inhibition of voltage-gated sodium channels. The compound's primary use is in analytical chemistry, where it serves as an internal standard for the quantification of mepivacaine in biological samples using mass spectrometry. |
| ln Vivo |
Mepivacaine-d3 does not have specific in vivo biological activity as it is used as an analytical standard. The compound is the deuterated form of mepivacaine, a local anesthetic used in dental procedures and minor surgeries. Mepivacaine-d3 is used as an internal standard for analytical applications rather than for its anesthetic effects. Its deuterium labeling allows for precise pharmacokinetic and metabolic analysis of mepivacaine in biological samples.
|
| Enzyme Assay |
Mepivacaine-d3 does not have a specific in vitro enzyme/receptor binding assay as it is used as an analytical standard. The compound is typically used as an internal standard in mass spectrometry for the quantification of mepivacaine in biological samples. For analytical applications, the compound is used to measure mepivacaine concentrations in plasma, urine, or tissue samples, allowing for precise pharmacokinetic and metabolic studies.
|
| Cell Assay |
Mepivacaine-d3 does not have specific cellular assays as it is used as an analytical standard. The compound is typically used in analytical chemistry applications rather than in cell-based studies. For research purposes, the compound is handled as a deuterated solvent or internal standard for mass spectrometry analysis.
|
| Animal Protocol |
Mepivacaine-d3 does not have specific in vivo animal study protocols as it is used as an analytical standard rather than a therapeutic compound. The compound is typically used in analytical applications to quantify mepivacaine or related compounds in biological samples from animal studies. It can be administered to animals, and its levels in plasma or tissues are measured to study the pharmacokinetics of mepivacaine.
|
| ADME/Pharmacokinetics |
Mepivacaine-d3 is used as an internal standard in analytical chemistry, and its pharmacokinetic properties are not relevant to its use as a standard. The compound has a molecular weight of 249.37 g/mol and is a stable isotope-labeled compound. It is typically stored under standard laboratory conditions at room temperature. The isotopic enrichment is 99% 2H. Detailed ADME parameters such as half-life, bioavailability, and tissue distribution are not applicable as the compound is used as an analytical standard.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for mepivacaine-d3 as it is used as an analytical standard. The parent compound, mepivacaine, is a local anesthetic that is generally well-tolerated at therapeutic doses. As a research chemical, mepivacaine-d3 should be handled with standard safety precautions for handling chemical reagents. The compound is not approved for human therapeutic use as a deuterated agent. Researchers should consult the material safety data sheet (MSDS) for detailed safety and handling information.
|
| References | |
| Additional Infomation |
Mepivacaine-d3 is the deuterium-labeled form of the local anesthetic mepivacaine. It has a molecular formula of C15H19D3N2O and a molecular weight of 249.37 g/mol. Mepivacaine-d3 is a stable isotope-labeled compound used in pharmacokinetic and pharmacodynamic studies. The introduction of deuterium enhances the molecule's stability, allowing for precise pharmacokinetic and metabolic analysis. The isotopic enrichment is 99% 2H.
|
| Molecular Formula |
C15H19D3N2O
|
|---|---|
| Molecular Weight |
249.37
|
| Exact Mass |
249.192
|
| CAS # |
1346597-90-7
|
| Related CAS # |
Mepivacaine;96-88-8
|
| PubChem CID |
71749963
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3 (Predicted)
|
| Boiling Point |
383.1±42.0 °C at 760 mmHg (Predicted)
|
| Flash Point |
185.5±27.9 °C (Predicted)
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C (Predicted)
|
| Index of Refraction |
1.567 (Predicted)
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N1CCCCC1C(=O)NC2=C(C=CC=C2C)C
|
| InChi Key |
INWLQCZOYSRPNW-HPRDVNIFSA-N
|
| InChi Code |
InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)/i3D3
|
| Chemical Name |
N-(2,6-dimethylphenyl)-1-(trideuteriomethyl)piperidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0101 mL | 20.0505 mL | 40.1011 mL | |
| 5 mM | 0.8020 mL | 4.0101 mL | 8.0202 mL | |
| 10 mM | 0.4010 mL | 2.0051 mL | 4.0101 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
